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[57] ABSTRACT
Radioactive microspheres for radiation synovectomy of 
arthritic joints in a mammal comprises a biodegradable 
glass material and a beta radiation emitting radioisotope 
chemically dissolved in and distributed substantially 
uniformly throughout the glass material. The biode­
gradable glass material may be lithium silicate, lithium 
aluminosilicate, lithium aluminoborate, lithium germa- 
nate, lithium aluminogermanate, potassium silicate, po­
tassium aluminosilicate, potassium aluminoborate, po­
tassium germanate or potassium aluminogermanate and 
the beta radiation emitting radioisotope may be samari­
um-153, holmium-166, erbium-169, dysprosium-165, 
rhenium-186, rhenium-188 or yttrium-90. Method for 
preparing such microspheres and for carrying out radia­
tion synovectomy of arthritic joints utilizing such mi­
crospheres are also disclosed.



















































COMPOSITION AND METHOD FOR RADIATION 
SYNOVECTOMY OF ARTHRITIC JOINTS
This is a division of application Ser. No. 150,154, filed 
Jan. 29, 1988, now U.S. Pat. No. 4,889,707.
BACKGROUND OF THE INVENTION
This invention relates to radiation synovectomy for 
arthritic joints and, more particularly, to novel biode­
gradable and biologically compatible glass micro­
spheres or beads and their use in carrying out radiation 
synovectomy of arthritic joints.
Current medical management of rheumatoid arthritis 
includes patient education, appropriate rest and physi­
cal therapy, and the use of anti-inflammatory drugs for 
relief of pain and inflammation. Ruddy, S., The Man­
agement of Rheumatoid Arthritis. Textbook of Rheu­
matology, 2nd ed., W. B. Saunders Co. Philadelphia, 
1985, p. 979. Patients who do not respond to these mo­
dalities may require therapy With anti-malarial agents 
such as hydroxychloroquine (Dell, C.L., Hydroxychlo­
roquine Sulfate in Rheumatoid Arthritis: Long-Term 
Response Rate and Predictive Parameters, American 
Journal of Medicine, 75:46, 1983) or remission inducing 
agents including gold salts (Empire Rheumatism Coun­
cil, Gold Therapy in Rheumatoid Arthritis: Final Re­
port of a Multicentre Controlled Trial, Ann. Rheum. 
Dis. 20:315, 1961), penicillamine (Multicentre Trial 
Group: Controlled Trial of d(-) Penicillamine in Severe 
Rheumatoid Arthritis, Lancet, 1:275, 1973), or azathio- 
prine (Abel, T. et al., Long-Term Effects of Azathio- 
prine in Rheumatoid Arthritis, Arthritis Rheum. 21:539, 
1978). Despite the efficacy of these drugs, patient re­
sponse is variable and improvement may not occur until 
treatment has extended for three to six months. When a 
few joints remain swollen and painful and interfere with 
the patient’s progress, intra-articular instillation of corti­
costeroids may be used as an adjunct to systemic ther­
apy. This local remedy, however, may be ineffective or 
may last only a few days (Owen, D.S., Aspiration and 
Injection of Joints and Soft Tissues, Textbook of Rheu­
matology, supra, p 546).
Surgery may be used in several different ways to help 
the patient with rheumatoid arthritis. Surgery can help 
relieve pain, it can prevent further deformity and loss of 
function, or at least allay these problems, and when 
destruction has occurred, reconstructive procedures 
can return function to a part or a limb. Sledge, C.B., 
Introduction to the Surgical Management of Arthritis, 
Textbook of Rheumatology, supra, p. 1787.
Most of the operations done on rheumatoid patients 
relieve pain. Fusions of joints, total joint replacement 
and synovectomy are examples of procedures that sig­
nificantly reduce pain. Conaty (Conaty, J.P., Surgery of 
the Hip and Knee in Patients with Rheumatoid Arthri­
tis, Journal of Bone and Joint Surgery, 55(A):301, 1973) 
states that in rheumatoid arthritis, synovectomy was the 
most successful procedure for preserving motion of a 
joint, except for total joint arthroplasty. This proce­
dure, then, is preventive. Even so, eventually the syno­
vium regenerates and the process continues (Patzakis, 
M.J. et al., A Visual, Histological, and Enzymatic Study 
of Regenerating Rheumatoid Synovium in the Syno- 
vectomized Knee, Journal of Bone and Joint Surgery, 
55(A):287, 1973). Total joint surgery will relieve any or 
all of the afore-mentioned disabilities, but brings with it 
other problems that must be taken into consideration by
the surgeon. Some of these are: 1) cost, 2) the risk of 
infection, 3) the fact that the implants may come loose 
and be painful, and 4) the fact that the implant may 
break with unusual use.
Chemical and radioisotope synovectomy (synovior- 
thesis) constitutes an effective alternative to operative 
therapy. The advantages of synoviorthesis are: 1) simple 
techniques employed in their use, 2) decreased or no 
hospitalization, 3) lower costs, 4) early and easier mobi­
lization of the patient, and 5) a surgical synovectomy 
remains an alternative treatment should the synovior­
thesis not work.
In general, the results of radioisotope synoviorthesis 
appear to be superior to those attained with chemical 
synovectomy. (Menkes, C.J., et al. La Synoviorthese a 
L’acide Osmique Chez L’hemophilie, Rev. Rhum. 
40:255, 1973; Oka, M., et al., The Fate and Distribution 
of Intra-Articularly Injected Osmium Tetraoxide, Acta 
Rheum. Scand., 16:271, 1970; Delbarre, F., et al., La 
Synoviorthese par les Radio-Isotopes a la Main et au 
Poignet, Rev. Rhum., 40:205, 1973). Some chemical 
agents that have been used are thio-tepa (Flatt, A.E., 
Intra-Articular Thio-Tepa in Rheumatoid Disease of 
the Hands, Rheumatism, 18:70, 1962; Fearnley, M.D., 
Intra-Articular Thio-Tepa Therapy in Rheumatoid Ar­
thritis, Ann. Phys. Med., 7:294, 1963; Zuckner, J., et al., 
Evaluation of Intra-Articular Thio-Tepa in Rheumatoid 
Arthritis, Ann. Rheum. Dis., 25:178, 1966; Gross, D., 
Chemische Synovektomie mit Senfgas bei Primar Chro- 
nischer Polyarthritis, Z. Rheumforsch, 22:456, 1963; 
Mondragon Kalb, M., Thiotepa en al Tratamiento de la 
Arthritis Rhumatoide, Medicina, 15:82, 1965), osmic 
acid (Menkes, C.J., et al., La Synoviorthese a L’acide 
Osmique Chez L’hemophilie, Rev. Rhum., 40:255,1973; 
Oka, M., et al., The Fate and Distribution of Intra- 
Articularly Injected Osmium Tetraoxide, Acta Rheum. 
Scand., 16:271, 1970; Von Reis, G., et al., Intra-Articu- 
lar Injections of Osmic Acid in Painful Joint Affections, 
Acta Med. Scand. Supp ., 259: 27, 1951; Berglof, F.E., 
Further Studies on the Use of Osmic Acid in the Treat­
ment of Arthritis, Acta Rheum. Scand., 10:92, 1964; 
Martio, J., et al., Intra-Articular Osmic Acid in Juvenile 
Rheumatoid Arthritis, Scand. J. Rheumatol, 1:5, 1972; 
Brattstrom, H., et al., Kombinierte Chemische und Op­
erative Synovektomie es Kniegelenks, Orthapade, 2:73, 
1973; Jakubowski, S., et al., Indikatronen zur Synovek­
tomie bei pcP, orthopade, 2:6, 1973), varicoid (Tillman, 
K., Chemische Synovektomie, Orthopade, 2:10, 1973) 
and gold (Delbarre, F., et al., supra). Radioactive sub­
stances include Gold-198, Yttrium-90 citrate, Yttrium- 
90 resin, Rhenium-186, Erbium-169, Yttrium-90 ferric 
hydroxide, Radium-224 and Phosphorus-32 chromic 
phosphate (Sledge, C.B., supra).
Beta-emitting radionuclides are considered the most 
useful for radiotherapeutic applications because of the 
moderate linear energy transfer (LET) of the ionizing 
particle (electron) and its intermediate range (typically 
several millimeters in tissue). In contrast, gamma rays 
deliver dosage at lower levels over much greater dis­
tances, thus hampering the localization of the dose and 
diluting its effect. Alpha particles represent the other 
extreme; they deliver very high LET dosage, but have 
an extremely limited range and must, therefore, be in 
intimate contact with the cells of the tissue to be treated. 
In addition, alpha emitters are generally heavy metals, 
which limits the possible chemistry and presents undue 

















It is fortuitous that beta emitters, the most useful 
radiotherapeutic radionuclides, are also the ones most 
copiously produced by neutron capture in nuclear reac­
tors, the most powerful sources of radioisotopes. Reac­
tor-produced isotopes number in the thousands, giving 
researchers a wide choice of isotopes of various half- 
lives, beta energies, gamma emissions, and chemical 
properties. Gamma emissions, while not as useful for 
therapy as beta emissions, play an important role in that 
they permit the distribution of radioisotope in the body 
to be observed using an Anger gamma ray camera or 
single photon computed tomography (SPECT) instru­
ment. This permits direct observation and, to some 
extent, quantification of radionuclide leakage from an 
organ or a joint and also provides positive verification 
of the potency of joint injection and distribution of the 
radionuclide in the research animal.
Treatment of the different depths of diseased syno­
vium in joints of disparate size, such as the finger joints 
and the knee, requires isotopes of different average beta 
range. It is important to achieve a “kill” of sufficient 
depth to be efficacious without causing significant ne­
crosis of overlying normal tissues.
The effectiveness of a radioisotope depends upon the 
fact that it gives off beta radiation which kills tissue 
along with the fact that it gives off no alpha and little 
gamma radiation. The latter type of radiation penetrates 
too far, affecting tissues adversely, whereas beta radia­
tion has a short penetration distance, varying in millime­
ters for each radioisotope. Radioisotopes also have dif­
ferent half-lives, some being far too long or too short for 
any practical use. These factors, then, have to be con­
sidered in the application of a radioisotope for synovior- 
thesis.
Sledge et al. (Treatment of Rheumatoid Synovitis of 
the Knee with Intra-Articular Injection of Dysprosium- 
165 Ferric Hydroxide Macroaggregates, Arthritis and 
Rheumatism, 29(2):153, 1986) have used macroaggre­
gates of ferric hydroxide (FHMA) combined with dys- 
prosium-165. This compound does present the problem 
of some leakage to local lymph nodes and other tissues 
Also, dysprosium-165 has a half-life of 2.3 hours, mak­
ing it necessary for the patient to be close to a nuclear 
reactor, severely limiting the use of this radioisotope. 
Even with these drawbacks, the clinical results were 
noteworthy, as 80% of patients treated for chronic 
synovitis of the knee with dysprosium-165-FHM A were 
improved at one year, and nearly 90% of patients with 
stage 1 roentgenographic changes had excellent, good, 
or fair results (Sledge, et al., Intra-Articular Radiation 
Synovectomy, Clinical Orthopaedics and Related Re­
search, 182:37, 1984). These results and the results of 
others (Boerbooms, A.M., et al., Radio-Synovectomy in 
Chronic Synovitis of the Knee Joint in Patients with 
Rheumatoid Arthritis, European Journal of Nuclear 
Medicine, 10:446, 1985; Multicentre Trial Group: Intra- 
Articular Radioactive yttrium and Triamcinolone Hex- 
aoetonide: An Inconclusive Trial, Ann. Rheum. Dis., 
43:620, 1984; Kyle, V., et al., Yttrium-90 Therapy and 
99mTc Pertechnetate Knee Uptake Measurements in the 
Management of Rheumatoid Arthritis, Annals of the 
Rheumatic Diseases, 42:132, 1983; Rosenthall, L., Use 
of Radiocolloids for Intra-Articular Therapy for Syno­
vitis, In Therapy in Nuclear Medicine, Grune and Strat­
ton, Inc., New York, 1978, p. 147; Spooren, P. et al., 
Synovectomy of the Knee with 90-Y, European Journal 
of Nuclear Medicine, 10:441, 1985) show that radiation
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synoviorthesis has a role in the treatment of inflamma­
tory synovitis.
In our copending, coassigned application for U.S. 
pat. ser. No. 673,123, filed Nov. 19, 1984, we disclose 
novel microspheres for use in the radiation therapy of 
liver cancer and other cancerous or tumor bearing tis­
sue. Such microspheres have not, however, been used 
or suggested for use in radiation synovectomy of ar­
thritic joints and may not be suitable for use in radiation 
synovectomy by reason of the radionuclides incorpo­
rated therein having relatively long physical half-lives.
There is a continuing need, therefore, for improved 
microspheres and methods for radiation synovectomy 
of arthritic joints.
SUMMARY OF THE INVENTION
Among the several objects of the invention may be 
noted the provision of novel microspheres for use in 
radiation synovectomy of arthritic joints; the provision 
of such microspheres containing beta emitting radioiso­
topes which have a moderately abundant low energy 
gamma photon that is in the energy range used for 
nuclear medicine imaging; the provision of such micro- 
spheres which are biodegradable and advantageously 
gradually dissolve after they are no longer radioactive; 
the provision of such microspheres which are prepared 
in a nonradioactive form and may then be subjected to 
an effective amount of neutron irradiation to produce 
microspheres containing the desired beta emitting radi­
oisotope; and the provision of methods for carrying out 
radiation synovectomy of arthritic joints and for pre­
paring biodegradable microspheres for use in radiation 
synovectomy. Other objects and features will be in part 
apparent and in part pointed out hereinafter.
Briefly, the present invention is directed to novel 
radioactive microspheres useful for radiation synovec­
tomy of arthritic joints. These radioactive microspheres 
comprise a biodegradable or biologically compatible 
glass material containing a beta radiation emitting radio­
isotope chemically dissolved therein. In a preferred 
embodiment, such microspheres have been subjected to 
an acid wash to produce a sparingly soluble coating on 
their outer surface so that the microspheres gradually 
dissolve after they are no longer radioactive.
Another aspect of the invention is the provision of 
novel microspheres which are initially nonradioactive 
and which, upon being subjected to an effective amount 
of neutron irradiation, will produce a beta radiation 
emitting radioisotope thereby rendering the micro­
spheres suitable for use in radiation synovectomy of 
arthritic joints while avoiding the handling of radioac­
tive elements during initial production of the micro- 
spheres.
A still further aspect of the invention resides in the 
provisions of novel methods for carrying out radiation 
synovectomy of arthritic joints utilizing the novel radi­
oactive microspheres of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. 1 and 2 are graphs showing the dissolution 
(weight loss in mg/cm2) of two different glass composi­
tions of the invention in deionized water at 37° C. as a 
function of time.
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS
In accordance with the present invention has now 

















may be advantageously employed in radiation synovec­
tomy of arthritic joints while substantially avoiding 
systemic leakage of the beta radiation emitting radioiso­
tope from the joint being treated and permitting greater 
control of the particle size of such microspheres. The 
radioactive microspheres of” the invention are prepared 
from novel microspheres which may be manufactured 
and sized before radioactivity is induced providing the 
advantage of working only with nonradioactive materi­
als during initial production of the microspheres.
In a first embodiment of the invention, the novel 
radioactive microspheres are comprised of a biodegrad­
able glass material selected from the group consisting of 
lithium silicate, lithium aluminosilicate, lithium 
aluminoborate, lithium germanate and lithium alumino- 
germanate and containing a beta radiation emitting 
radioisotope chemically dissolved in and distributed 
substantially uniformly throughout the glass material, 
the radioisotope being samarium-153, holmium-166, 
erbium-169, dysprosium-165, rhenium-186, rhenium-188 
or yttrium-90. It has been found that lithium silicate, 
lithium aluminosilicate, lithium aluminoborate, lithium 
germanate or lithium aluminogermanate biodegradable 
glasses are particularly suitable for the purposes of the 
invention since lithium does not become a gamma emit­
ter upon being subjected to neutron irradiation whereas 
sodium, calcium and phosphorus, components of other­
wise biodegradable glasses, do become gamma emitters 
with unacceptably long half-lives upon neutron irradia­
tion or become beta emitters which have undesirably 
long half-lives or which bond to bone. For example, the 
composition of the bioactive and partially biodegrad­
able glass composition known as “Bioglass” is 45% 
Si0 2 , 24.5% Na20 , 24.5% CaO and 6 % P20 5 (Hench, 
Ceramic Implants for Humans, Advanced Ceramic 
Materials, l(4):306-324, 1986), and this glass is unsuit­
able because of the sodium, calcium and phosphorous it 
contains.
Also, while use of the above-noted lithium glass ma­
terials is preferred, potassium glasses selected from the 
group consisting of potassium silicate, potassium alumi­
nosilicate, potassium aluminoborate, potassium germa­
nate and potassium aluminogermanate may also be used 
in the practice of the invention. While potassium does 
become a gamma emitter upon being subjected to neu­
tron irradiation, the radioisotope potassium-42 thus 
produced has an acceptably short half-life of approxi­
mately 12 hours. Therefore, when such potassium glass 
materials are employed, administration of the radioac­
tive microspheres containing them is delayed for a suffi­
cient time to permit the potassium-42 to decay to ac­
ceptable levels.
The above-noted beta radiation emitting radioiso­
topes are also particularly suitable for use in the present 
invention. Samarium-153 (46.3 hr. half-life) and holmi- 
um-166 (26.8 hr. half-life) can readily be dissolved in 
silicate, aluminosilicate or aluminoborate glasses, have 
good activation properties in a nuclear reactor, possess 
imageable gamma rays, exhibit low toxicity and have 
half-lives long enough for distribution of the radioactive 
microspheres of the invention containing them.
Holmium-166 is produced by neutron capture on 
100% abundant, stable holmium-165 with thermal neu­
tron and resonance neutron cross sections of 61.2 and 
670 bams, respectively. It decays with a 26.83 hour 
half-life by emission of 1.855 MeV (51%) and 1.776 
MeV (48%) maximum energy beta particles with a 
maximum range in water of about 8.0  mm and an aver-
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age range of about 2 mm. Since dysprosium-165 emits a 
beta particle of slightly lower maximum energy (1.31 
MeV) and has proven efficacious in human knee radia­
tion synovectomies, it appears that holmium-166 has 
sufficient penetration for this application. Ho-166 also 
emits an 80.5 Kev gamma-ray in 6.2% abundance and 
thus is imageable by conventional techniques.
Samarium-153 is produced by neutron capture of 
natural or isotopically enriched samarium-152 with 
thermal and resonance neutron cross sections of 210  and 
3,020 bams, respectively. It decays by beta emissions of
0.810 MeV (20%), 0.710 MeV (49%), and 0.640 MeV 
(30%) maximum energies with concomitant ranges of 
about 2.3 mm maximum and 0.8 mm average distance, 
respectively. Sm-153 has a physical half-life of 46.27 
hours and produces a highly imageable 103 KeV 
gamma ray with an abundance of 29.8%, decaying to 
stable Eu-153.
Samarium-153 and holmium-166 are both chemically 
compatible and capable of being incorporated into 
many types of glass in which no other significant radio­
activities induced by neutron bombardment will be 
present after about one day of decay. Erbium-169, dys­
prosium-165, rhenium-186, rhenium-188 (from rhenium- 
185 and rhenium-187) and yttrium-90 also possess the 
desired properties rendering them suitable for use as the 
radioisotope in this embodiment of the invention.
As mentioned, in the first embodiment of the inven­
tion generally described above, a biodegradable glass 
material is selected from the group consisting of lithium 
silicate, lithium aluminoborate, lithium aluminosilicate, 
lithium germanate and lithium aluminogermanate or the 
corresponding potassium glass materials. Such glasses 
may be doped with samarium oxide (Sm20 3 ), holmium 
oxide (Ho20 3) or oxide of erbium, dysprosium, rhenium 
or yttrium in preparing the novel nonradioactive and 
radioactive microspheres of the invention. By way of 
example, such biodegradable glasses so doped may have 
the following illustrative compositions by weight per­
cent:
20.1% LaiO-74.9% SiCV5% SmaOs;
21.8% Li20-3.9% Al20 3-69.3% Si02-5%Sm20 3.
19.7% Li20-13.1% B20 3-62.2% Si02-5% Sm20 3;
It will be understood that other lithium silicate, lithium 
aluminosilicate, lithium aluminoborate, lithium germa­
nate and lithium aluminogermanate glass materials or 
the corresponding potassium glass materials suitably 
doped with samarium, holmium, erbium, dysprosium, 
rhenium or yttrium may also be used in the practice of 
the invention.
In a second embodiment of the invention, the novel 
radioactive microspheres are comprised of a biologi­
cally compatible glass material selected from the group 
consisting of magnesium aluminosilicate and aluminosil­
icate glass material and containing a beta radiation emit­
ting radioisotope chemically dissolved in and distrib­
uted substantially uniformly through the glass material, 
the radioisotope being samarium-153, holmium-166, 
erbium-169, dysprosium-165, rhenium-186 or rhenium- 
188 . While such glass materials are not biodegradable, 
they are biologically compatible and are useful in the 
practice of the invention. Such glass compositions may 
be prepared by doping magnesium aluminosilicate or 
alumino-silicate glass materials with oxides of samarium 
(Sm20 3), holmium (Ho20 3), erbium (Er20 3), dys­















cific examples of such glass compositions include the 
following compositions by weight percent.
20% MgO-21% Al20 3-52% Si02-7% Sm20 3.
40% Y2O3-20% Al2O3-40% Si02.
40% Sm2O3-20% Al2O3-40% Si02.
20% MgO-21% Al20 3-52% Si02-7% Ho20 3- 
20% MgO-21% Al20 3-52% Si02-7% R e02; ’
It will be understood that other magnesium aluminosili­
cate or aluminosilicate glass materials suitably doped 
with samarium, holmium, erbium, dysprosium or rhe­
nium may also be used in the practice of the invention.
The microspheres of the present invention may be 
prepared from a homogeneous mixture of powders (i.e. 
the batch) that is melted to form the desired glass com­
position. The exact chemical compounds or raw materi­
als used for the batch is not critical so long as they 
provide the necessary oxides in the correct proportion 
for the melt composition being prepared. For example, 
if a samarium doped lithium silicate glass is being made, 
then Sm20 3, Li2C 0 3 and Si02 Powders would be used 
as the batch raw materials. The purity of each raw 
material is typically greater than 99.9%. After either 
dry or wet mixing of the powders to achieve a homoge­
neous mixture, the mixture may be placed in a platinum 
crucible for melting. High purity alumina crucibles can 
also be used if at least small amounts of alumina can be 
tolerated in the glass being made. The raw materials 
must not contain impurities that become radioactive 
from neutron irradiation.
The crucibles containing the powdered batch are 
then placed in an electric furnace heated to 1500 to 
1600° C. depending upon the composition. In this tem­
perature range, the batch melts to form a liquid which is 
stirred several times to improve its chemical homogene­
ity. The melt should remain at 1500 to 1600° C. until all 
the solid batch is totally dissolved. This usually requires 
2 to 5 hours duration. When melting and stirring is 
complete, the crucible is removed from the furnace and 
the melt is quickly quenched to a glass by pouring the 
melt onto a cold steel plate or into cold clean water. 
This procedure breaks the glass into fragments, which 
aids and simplifies crushing the glass to a fine powder 
(less than 400 mesh). The powder is then sized and 
spheridized for use.
The quenched and broken glass is first crushed to 
about minus 100 mesh particle size using a mortar and 
pestle. The minus 100 mesh material is then ground 
using a mechanized mortar and pestle or ball mill until 
it passes a 400 mesh sieve. The minus 400 mesh particles 
(37 microns in diameter) may be stored in a dry con­
tainer until used.
The particles are formed into glass microbeads or 
microspheres by introducing the minus 400 mesh parti­
cles into a gas/oxygen flame where they are melted and 
a spherical liquid droplet is formed by surface tension. 
This droplet is rapidly cooled before it touches any 
solid object so that its spherical shape is retained in the 
solid. Just prior to spheridizing, the minus 400 mesh 
powder is rescreened through a 400 mesh sieve to de­
stroy any large agglomerates that may have formed 
during storage. The minus 400 mesh powder is then 
placed in a vibratory feeder located above the gas/oxy- 
gen burner. The powder is slowly vibrated into a verti­
cal glass tube which guides the powder particles di­
rectly into the hot flame of the gas/oxygen burner. A 
typical rate for feeding the powder to the flame is 5 to 
25 grams/hour with the described apparatus. The flame 
of the burner is directed into a small metal container
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which catches the small glass beads or spheres as they 
are expelled from the flame.
After spheridization, the glass spheres are collected 
and rescreened with a sonic sifter. For use in the present 
invention, the fraction in the range of 3 to 30 microns in 
diameter is recovered since this is the desirable size for 
use in radiation synovectomy of arthritic joints. After 
screening, the microspheres in this size range are exam­
ined with an optical microscope and are then washed 
with a weak acid (HC1, for example), filtered and 
washed several times with reagent grade acetone. The 
washed beads or spheres are then heated in a furnace in 
air to 500-600° C. for 2-6 hours to destroy any organic 
material therein.
The final step is to examine a representative sample of 
the microspheres in the selected size range or fraction in 
a scanning electron microscope. The size, range and 
shape of the beads or spheres are evaluated, and the 
quantity of undersize beads (less than 3 microns in diam­
eter) is determined along with the concentration of 
non-spherical particles. The composition of the beads 
can be checked by energy dispersive x-ray analysis to 
confirm that the composition is correct and that there is 
an absence of chemical contamination.
The glass microspheres are then ready for activation 
by being subjected to an effective amount of neutron 
irradiation which will produce a beta radiation emitting 
radioisotope of samarium-153, holmium-166, erbium- 
169, dysprosium-165, rhenium-186, rhenium-188 or yt- 
trium-90, the amount depending upon the particular 
isotope of these elements that has been chemically dis­
solved and uniformly distributed throughout the glass 
material. The resulting radioactive microspheres of the 
invention have beta radiation emitting energies highly 
suitable for radiation synovectomy of arthritic joints 
and also provide gamma ray emissions suitable for nu­
clear medicine imaging devices.
In accordance with the invention, the radioactive 
microspheres prepared as described may be adminis­
tered to the afflicted joints by intra-articular injection or 
by other suitable means of administration. The micro- 
spheres are believed to be chemically durable in joint 
fluids and mechanically contained within the joint cav­
ity. Moreover, upon administration, they become dis­
tributed reasonably uniformly along the synovial mem­
brane and emit beta radiation of sufficient range to fully 
or substantially fully irradiate the thickness of the mem­
brane without giving significant dosage to more distant 
joint structures. Also, inasmuch as the thickness of the 
diseased membrane varies in different joints, the present 
invention makes possible the preparation of micro­
spheres doped with a different energy beta emitter for a 
finger joint than for a knee, for example.
Further, the present invention provides smooth mi­
crospheres which constitute a preferred shape over 
irregular, jagged particles with sharp edges and comers 
for the purpose of radiation synovectomy of arthritic 
joints. The smooth surface of a sphere should be more 
tissue compatible and less irritating than other shapes. 
The smooth shape of the microspheres of the invention 
should also cause less friction, mechanical wear and 
inflammation in a joint with moving parts than irregu­
larly shaped particles. Heretofore, radioactive micro­
spheres of the type provided by the present invention 
have not been available nor have glass microspheres of 

















While, as indicated, the microspheres of the present 
invention may be of various sizes, it is preferred for 
radiation synovectomy of arthritic joints that the micro- 
spheres have a diameter within the range of about 3 to 
30 micrometers (microns).
To localize the desired radiation to the affected joint, 
the radioactive element is chemically dissolved in a host 
glass material which is insoluble in the body. The es­
cape or leakage of the radioactive material from the 
joint has been a major problem with other types of 
materials (e.g. colloids) previously used in this type of 
radiation therapy and an insoluble glass should prevent 
any leakage since the radioactive material cannot es­
cape from insoluble glass microspheres. Also, for use in 
human joints, there is a perceived advantage to using 
glass beads or microspheres which gradually dissolve 
after they are no longer radioactive, i.e. which are bio­
degradable. Accordingly, in accordance with the pres­
ent invention, it is preferred to employ the biodegrad­
able glass microspheres which are initially insoluble 
during the period of time the bead is radioactive (i.e. 
few weeks) and which then gradually starts to dissolve 
and eventually disappear.
Biodegradable glass microspheres having such de­
sired characteristics may be prepared through another 
aspect of the present invention by treating the above- 
described biodegradable lithium silicate, lithium alumi­
nosilicate, lithium aluminoborate, lithium germanate, 
lithium aluminogermanate or corresponding potassium 
glass microspheres in such a way as to form an insoluble 
or sparingly soluble coating on its outer surface. This 
can be done by washing such glasses in common acids 
such as hydrochloric acid, nitric acid or sulfuric acid 
and thereby replace the lithium or potassium ions on the 
outer surface with protons or H3O+. The results of this 
dealkalization process is to produce a thin layer (skin) 
on the surface of the glass beads or microspheres whose 
solubility is less than of the underlying glass. A glass 
bead with such a dealkalized surface initially dissolves 
slowly until the more durable outer surface layer is 
dissolved, and then starts to dissolve faster as the less 
durable, underlying glass is exposed to the surrounding 
media.
Thus, washing glass microspheres of the invention in 
common acids is an exemplary and practical means of 
achieving the desired dissolution characteristics re­
quired for radioactive, biodegradable glass micro­
spheres for use in human joints. It will be understood by 
those skilled in the art that various factors are important 
to the dissolution characteristics of the dealkalized sur­
face or skin. These are: (1) the starting glass composi­
tion, especially the amount of alkali ion (i.e. lithium or 
potassium) present; (2) concentration and type of acid 
employed; (3) temperature of the acid; (4) time of acid 
treatment; and (5) heat treatment of dealkalized surface 
after acid wash. It will also be understood by those 
skilled in the art that in addition to acid washing, other 
procedures such as heating a glass in various gases such 
as SO2 and F2 can be used to produce a more chemically 
durable dealkalized skin on the lithium and potassium 
glasses described above.
The following examples further illustrate the inven­
tion.
Example 1
31 rabbits were injected with about 5 mg each of 
non-radioactive glass microspheres (20-30 microns in 
size) having the composition by weight: 40% Y2O3-
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20% Al2C>3-40% SiC>2. The injections were made in the 
left stifles (knee) using Angiovist 370 contrast medium 
(diatrizoate meglumine and diatrizoate sodium; Berlex 
Laboratories, Incorporated) as a suspending medium, 
with a control injection of Angiovists in the right stifle. 
The rabbits showed no ill effects whatsoever over peri­
ods ranging from 48 hours to three months. Upon sacri­
fice at intervals of 2 to 90 days, the stifles were all dis­
sected and slides prepared of various joint tissues. Ex­
amination of the slides revealed microspheres only 
along the synovium with no spheres apparent in the 
Underlying fat tissue or lymph nodes, and no mechani­
cal abrasion or damage to the cartilage or other joint 
structures.
Example 2
FIGS. 1 and 2 show the dissolution (weight loss in 
mg/cm2) of two different glass compositions as shown 
thereon in deionized water at 37° C. as a function of 
time. The straight lines labeled 3 mos. and 6  mos. desig­
nate the dissolution needed for a 30 micro bead or 
sphere to dissolve in 3 and 6  months, respectively. In 
addition to untreated specimens (control), each figure 
also shows the dissolution of specimens of each glass 
composition washed in 1 N HC1 for 4 hours at either 25 
or 50° C.
The effectiveness of the acid wash in reducing the 
dissolution at short times is clearly evident in FIG. 1 for 
the specimen washed in HC1 at 25° C. In contrast to the 
unwashed control which showed an immediate weight 
loss, the sample washed in acid at 25° C. did not show 
any detectable weight loss for more than one week in 
deionized water. After about one week, the sample then 
began to dissolve as desired. Similar results are given in 
FIG. 2, except that acid washing at 50° C. was more 
effective for this glass because of its different composi­
tion.
These studies show that acid washing produces an 
insoluble surface skin which yields the dissolution char­
acteristics needed for radioactive, biodegradable glass 
microspheres for use in human joints.
Example 3
A. SAMPLE PREPARATION
The glass compositions in the following table were 
prepared from reagent grade chemicals. Batches yield­
ing 50 grams of glass were melted in platinum crucibles 
in an electric furnace at approximately 1350° C. The 
melt was held at 1350° C. for 1 to 2 h for fining and 
homogenization and then cast into steel molds to form 
bars measuring approximately l x  1X1X8 cm which 
were annealed at 500° C. for 30 min. and then slowly 
cooled to room temperature. Slabs approximately
0 .2  X 1 X 1 cm were cut from the bars and ground to 
rectangular shape using 180 grit silicon carbide paper.
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COMPOSITION OF GLASSES
Batch Composition (Weight %)
Glass Si02 Li20 a i2o 3 s m 2o 3
LSI 74.9 20.1 0.0 5.0
LS3 69.3 21.8 3.9 5.0
A portion of the LSI glass was broken and ground to 
— 200 mesh and wet milled for 6  h with methanol. The 
powder was then dried and screened through a 325 















fed into an oxygen/propane flame where surface ten­
sion caused the molten particles to become spheres.
B. SURFACE TREATMENTS
1. Sulfur Dioxide Gas
The glass slabs were placed in a tube furnace at either 
400 or 500° C'. SO2 gas was bubbled through Water at 
25° C. at an approximate rate of one bubble per second 
before flowing through the furnace. The treatment 
times were 90 min. at 400° C. and 15 or 45 min. at 500°
C. After removal from the furnace, the slabs were 
cooled, rinsed in distilled water to remove any lithium 
sulphate formed on the surface, and dried in an oven at 
100° C.
2. Washing in HC1
The glass was placed in a 0.1N HC1 solution in a 
beaker, magnetically stirred, rinsed in distilled water, 
and dried in air at 100° C. Initially, the effect of acid 
washing on the glasses for 2,4, 6 or 8 h at 25° C., 50° C., 
or 75° C. was examined. The time and temperature 
which gave the longest delay before dissolution com­
menced for LSI was 4 h at 25° C. an for LS3 was 4 h at 
50° C. These times and temperatures were used in subse­
quent heat treatments.
3. Washing in HC1 Followed by Heat Treatment
After washing in 0.1 N HC1 acid, the glass slabs were 
heated on a steel plate in a furnace to 350 or 400° C. At 
350° C., the slabs were heated for 10 or 30 min. and at 
400° C., the slabs were heated for 10, 30, 45, 60, or 90 
min. Microspheres of LSI were heated at 350° C. for 30 
min.
C. CHEMICAL DISSOLUTION 
MEASUREMENTS
After surface treatments, the glass slabs were 
weighed and their exact dimensions measured before 
placing them in polyethylene bottles containing 125 mL 
of distilled water (pH=7). The bottles were placed in 
an oven at 37° C., which is the temperature of the 
human body. The weight change of each slab was mea­
sured periodically by removing the slab from the bottle, 
drying it in an oven at 100° C., and weighing.
The average dissolution, D, of each sample was cal­
culated from the equation
D=(W0-W )/A
where W0was the initial weight of the original slab, 
W was the current weight of the slab, and A was the 
surface area of the slab. The dissolution was plotted 
against time.
Approximately 20 mg of microspheres made from the 
LSI glass were placed in polyethylene bottles contain­
ing 25 mL of distilled water and placed in an oven at 37° 
C. The microspheres were removed after 3 weeks for 
SEM analysis.
D. SEM ANALYSIS
Selected microspheres and slabs were mounted on a 
steel cylinder for SEM analysis. The slabs were broken 
and one piece was mounted to observe the corroded 
surface and the other to observe the fresh fracture sur­
face. The mounted slabs and microspheres were vapor 
coated with palladium.
Because the as-cut slabs had a very rough surface, 
polished slabs were used to see the effects of surface 
treatments. The surface of slabs of each glass was pol­
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ished to 1 micron using silicon carbide polishing paper 
and finally one micron AI2O3. These slabs were left 
untreated, treated in acid, or treated in acid followed by 
heat treatment (LSI; 350° C. for 30 minutes, LS3: 400° 
C. for 45 minutes). These samples were examined by 
SEM to determine if there was any change in the sur­
face due to washing in acid or washing in acid followed 
by heat treatment.
E. RESULTS AND CONCLUSIONS
LSI glass which contains 74.9% Si02, 20.1% Li20, 
and 5.0% S1X12O3 (weight %) is well suited for micro­
spheres that could be irradiated to treat rheumatoid 
arthritis. Acid washing followed by heating LSI re­
duced the dissolution to zero. Glasses acid washed and 
heated at 400° C. remained insoluble after 6 months. 
LSI glass acid washed then heated for 10 min. at 350° C. 
remained insoluble for 4 weeks and then began to dis­
solve at approximately half of the rate calculated for a 
30 micron sphere to dissolve in 6 months. If this glass 
continued to dissolve at this rate, then a 30 micron 
sphere treated in this way should be totally dissolved in 
12 months. Acid washing followed by heat treatment of 
LSI glass for 10 min. for 350° C. appears to create a 
temporarily insoluble surface layer which should pre­
vent the release of radioactive Sm-153.
SEM photographs of polished LS3 glass shows that 
acid washing followed by heating causes the surface to 
crack. This is probably due to a difference in thermal 
expansion between the bulk glass and the dealkalyzed 
layer. Acid washed then heated LS3 glasses began to 
dissolve immediately confirming no protective layer 
was created. In LS3 glass acid washed then heated at 
400° C., the initial dissolution rate paralleled the acid 
washed glass. After a few weeks, the dissolution de­
creased to almost zero, suggesting the corrosion process 
caused a protective layer to develop.
Washing LSI and LS3 glass in 0.1N HC1 delays the 
dissolution of LS3 for 5 days and of LSI for 7 days. 
Dissolution then begins at approximately the same rate 
as the untreated glass.
Exposure to hot sulfur dioxide gas decreases the dis­
solution of LSI glass in water at 37° C. but does not 
significantly affect the dissolution of LS3. No delay in 
dissolution occurred for either glass. Decreasing the 
temperature of the SO2 treatment may facilitate the 
dealkalyzing reactions of the SO2 and improve the 
chemical durability of the surface.
SEM photographs confirm that the acid washed then 
heated slabs of LSI which had a zero dissolution rate 
show no effect of corrosion, while the acid washed and 
untreated slabs showed cracking after two weeks in 
water.
Example 4
About 10 mg. of non-biodegradable glass micro­
spheres (10-20 microns in size) having the composition 
by weight: 20% MgO-21% Al203-52% Si02-7% 
Sm2 0 3 , were irradiated 10 minutes in a neutron flux of 
4E13/square cm/sec to make about 300 microcuries of 
Sm-153. The microspheres were irradiated in sealed, 
high density polyethylene vials having a volume of 
slightly more than 1 cc and drawn into 1 cc tuberculin 
syringes using Angiovist contrast medium as a suspend­
ing agent and injected into the stifles of healthy rabbits. 
Serial imaging was performed to ascertain leakage. 
















first four rabbits, but this appeared to occur due to 
leakage out of the injection puncture and possible tear 
in the joint capsule. A fifth rabbit injected through the 
cartilage in the front of the knee (i.e. through a thicker, 
self-sealing portion of the joint) exhibited no leakage.
In view of the above, it will be seen that the several 
objects of the invention are achieved and other advanta­
geous results attained.
As various changes could be made in the above prod­
ucts and methods without departing from the scope of 
the invention, it is intended that all matter contained in 
the above description or shown in the accompanying 
drawings shall be interpreted as illustrative and not in a 
limiting sense.
What is claimed is:
1. A nonradioactive microsphere adapted for radia­
tion synovectomy on arthritic joints in a mammal com­
prising a biologically compatible glass material selected 
from the group consisting of magnesium aluminosilicate 
and aluminosilicate and containing an isotope selected 
from the group consisting of samarium, holmium, er­
bium, dysprosium, and rhenium chemically dissolved in 
and distributed substantially uniformly throughout said 
glass material and which, upon being subjected to an 
effective amount of neutron irradiation, will produce a 
beta emitting radioisotope selected from the group con­
sisting of samarium-153, holmium-166, erbium-169, dys­
prosium-165, rhenium-186 and rhenium-188.
2. A microsphere as set forth in claim 1 wherein said 
glass material is magnesium aluminosilicate and said 
radioisotope is samarium-153.
3. A microsphere as set forth in claim 1 wherein said 
glass material is aluminosilicate and said radioisotope is 
samarium-153.
4. A microsphere as set forth in claim 1 wherein said 
glass material is magnesium aluminosilicate and said 
radioisotope is holmium-166.
5. A microsphere as set forth in claim 1 wherein said 
glass material is aluminosilicate and said radioisotope is 
holmium-166.
6 . A microsphere as set forth in claim 1 wherein said 
microsphere has a diameter in the range of about 3 to 
about 30 micrometers.
7. A microsphere as set forth in claim 1 wherein the 
composition of said microsphere is approximately 2 0 % 
by weight MgO, approximately 21% by weight AI2O3, 
approximately 52% by weight SiC>2 and approximately 
7% by weight Sm2 0 3 .
8 . A microsphere as set forth in claim 1 wherein the 
composition of said microsphere is approximately 2 0 % 
by weight AI2O3, approximately 40% by weight SiC>2 
and approximately 40% by weight Sm2 0 3 -
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9. A nonradioactive microsphere adapted for radia­
tion synovectomy of arthritic joints in a mammal com­
prising a biodegradable glass material selected from the 
group consisting of lithium silicate, lithium aluminosili­
cate, lithium aluminoborate, lithium germanate, lithium 
aluminogermanate, potassium silicate, potassium alumi­
nosilicate, potassium aluminoborate, potassium germa­
nate and potassium aluminogermanate and containing 
an isotope selected from the group consisting of samar­
ium, holmium, erbium, dysprosium, rhenium and yt­
trium chemically dissolved in and distributed substan­
tially uniformly throughout said glass material and 
which, upon being subjected to an effective amount of 
neutron irradiation, will produce a beta radiation emit­
ting radioisotope selected from the group consisting of 
samarium-153, holmium-166, erbium-169, dysprosium- 
165, rhenium-186, rhenium-188 and yttrium-90.
10. A microsphere as set forth in claim 9 wherein said 
glass material is lithium silicate and said radioisotope is 
samarium-153.
11. A microsphere as set forth in claim 9 wherein said 
glass material is lithium aluminosilicate and said radioi­
sotope is samarium-153.
12. A microsphere as set forth in claim 9 wherein said 
glass material is lithium aluminoborate and said radioi­
sotope is samarium-153.
13. A microsphere as set forth in claim 9 wherein said 
glass material is lithium silicate and said radioisotope is 
holmium-166.
14. A microsphere as set forth in claim 9 wherein said 
glass material is lithium aluminosilicate and said radioi­
sotope is holmium-166.
15. A microsphere as set forth in claim 9 wherein said 
glass material is lithium aluminoborate and said radioi­
sotope is holmium-166.
16. A microsphere as set forth in claim 9 wherein said 
microsphere has a diameter in the range of about 3 to 
about 30 micrometers.
17. A microsphere as set forth in claim 9 wherein the • 
composition of said microsphere is approximately 
20.1% by weight Li2 0 , approximately 74.9% by weight 
SiC>2 and approximately 5% by weight Sm2 0 3 .
18. A microsphere as set forth in claim 9 wherein the 
composition of said microsphere is approximately 
21.8% by weight Li2 0 , approximately 3.9% by weight 
AI2O3, approximately 69.3% by weight Si0 2  and ap­
proximately 5% by weight S1TI2O3.
19. A microsphere as set forth in claim 9 wherein the 
composition of said microsphere is approximately 
19.7% by weight Li2 0 , approximately 13.1% by weight 
B2O3, approximately 62.2% by weight Si0 2  and ap­
proximately 5% by weight Sm2 0 3 .
* * * * *
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